Etanexor is an investigational XPO1 inhibitor with low CNS penetrance and an acceptable tolerability profile, which yields antitumor activity in preclinical models of human multiple myeloma, ALL, AML, and gastric cancer.593, 594, 595, 596. The gene discussed is XPO1; the disease is acute myeloid leukemia.